COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 3rd May 2020. As a result, our offices will now be closed till 3rd May 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details.,, Mob. 8826373757, 8826859373, 9910947804

Print ISSN:-2395-1443

Online ISSN:-2395-1451


Current Issue

Year 2020

Volume: 6 , Issue: 1

Article Access statistics

Viewed: 701

Emailed: 0

PDF Downloaded: 195

Indian Journal of Clinical and Experimental Ophthalmology

Clinical study to evaluate safety and efficacy of tacrolimus 0.1% eye ointment in treatment of vernal keratoconjunctivitis

Full Text PDF Share on Facebook Share on Twitter

Author Details : Rajni Sethia, R N Kothari, Vivan Desai, Aditya Desai, Anjasi Patel

Volume : 3, Issue : 4, Year : 2017

Article Page : 444-449

Suggest article by email


Introduction: Vernal keratoconjunctivitis is a seasonally recurring, chronic, allergic bilateral inflammatory disorder of the conjunctiva and cornea caused due to immune mediated hypersensitivity reaction. Tacrolimus is an immunomodulator which induces suppression of T lymphocytes activity and causes reduction of ocular inflammation. Hence, in our present study we aim to evaluate the efficacy of 0.1% tacrolimus eye ointment as first line therapy in the management of Vernal Keratoconjunctivitis.
Materials and Methods: This was a clinical, prospective and interventional study including 100 eyes of 50 patients with VKC which were serially selected. 0.1% tacrolimus eye ointment was instilled twice daily over a period of 12 weeks. On every fortnightly follow up, patients were assessed for 5 symptoms and 4 signs and the severity was graded as 0 (normal), 1+ (mild), 2+ (moderate), or 3+ (severe)in order to evaluate the efficacy of the drug.
Results: There were 50 patients with VKC comprising of 41 males and 09 females. After treatment with Tacrolimus 0.1% eye ointment, there was statistically significant improvement in symptoms of VKC including itching, redness, photosensitivity, foreign body sensation and mucus discharge (P<0.001). Significant improvement in clinical signs of VKC including conjunctival hyperaemia, papillary hypertrophy, giant papillary conjunctivitis and limbal involvement (P<0.001) was seen at the end of the study. No significant adverse effects of tacrolimus were seen in these patients.

Conclusion: Topical 0.1% tacrolimus eye ointment is very effective in the treatment of Vernal Keratoconjunctivitis with minimal long term side effects.

Allergy, Immunosupressant, Inflammatory, Tacrolimus, Vernal keratoconjunctivitis.

How to cite : Sethia R, Kothari R N, Desai V, Desai A, Patel A, Clinical study to evaluate safety and efficacy of tacrolimus 0.1% eye ointment in treatment of vernal keratoconjunctivitis. Indian J Clin Exp Ophthalmol 2017;3(4):444-449

Copyright © 2017 by author(s) and Indian J Clin Exp Ophthalmol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0) (